Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5202068
Max Phase: Preclinical
Molecular Formula: C48H60Cl4N6O11S2
Molecular Weight: 1102.98
Associated Items:
ID: ALA5202068
Max Phase: Preclinical
Molecular Formula: C48H60Cl4N6O11S2
Molecular Weight: 1102.98
Associated Items:
Canonical SMILES: CN1Cc2c(Cl)cc(Cl)cc2[C@H](c2cccc(S(=O)(=O)NCCOCCOCCNC(=O)COCC(=O)NCCOCCOCCNS(=O)(=O)c3cccc([C@@H]4CN(C)Cc5c(Cl)cc(Cl)cc54)c3)c2)C1
Standard InChI: InChI=1S/C48H60Cl4N6O11S2/c1-57-27-41(39-23-35(49)25-45(51)43(39)29-57)33-5-3-7-37(21-33)70(61,62)55-11-15-67-19-17-65-13-9-53-47(59)31-69-32-48(60)54-10-14-66-18-20-68-16-12-56-71(63,64)38-8-4-6-34(22-38)42-28-58(2)30-44-40(42)24-36(50)26-46(44)52/h3-8,21-26,41-42,55-56H,9-20,27-32H2,1-2H3,(H,53,59)(H,54,60)/t41-,42-/m0/s1
Standard InChI Key: UQWBSVPMYCBVAF-COCZKOEFSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1102.98 | Molecular Weight (Monoisotopic): 1100.2516 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Jacobs JW, Leadbetter MR, Bell N, Koo-McCoy S, Carreras CW, He L, Kohler J, Kozuka K, Labonté ED, Navre M, Spencer AG, Charmot D.. (2022) Discovery of Tenapanor: A First-in-Class Minimally Systemic Inhibitor of Intestinal Na+/H+ Exchanger Isoform 3., 13 (7.0): [PMID:35859876] [10.1021/acsmedchemlett.2c00037] |
Source(1):